Ritesh Parajuli | UCI School of Medicine

Dr. Ritesh Parajuli, MD

Claim this profile

UC Irvine Health/Chao Family Comprehensive Cancer Center

Expert in Breast Cancer
Expert in Breast cancer
19 reported clinical trials
46 drugs studied

Area of expertise

1

Breast Cancer

Global Leader

Ritesh Parajuli, MD has run 16 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
ER positive
HER2 negative
2

Breast Cancer

Global Leader

Ritesh Parajuli, MD has run 11 trials for Breast cancer. Some of their research focus areas include:

Stage IV
ER positive
HER2 negative

Affiliated Hospitals

Image of trial facility.

UC Irvine Health/Chao Family Comprehensive Cancer Center

Image of trial facility.

UCI Health - Chao Family Comprehensive Cancer Center And Ambulatory Care

Clinical Trials Ritesh Parajuli, MD is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

More about Ritesh Parajuli, MD

Clinical Trial Related

2 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 8 Active Clinical Trials

Treatments Ritesh Parajuli, MD has experience with

  • Pembrolizumab
  • Paclitaxel
  • Tucatinib
  • Trastuzumab
  • Pertuzumab
  • Abemaciclib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Ritesh Parajuli, MD specialize in?

Is Ritesh Parajuli, MD currently recruiting for clinical trials?

Are there any treatments that Ritesh Parajuli, MD has studied deeply?

What is the best way to schedule an appointment with Ritesh Parajuli, MD?

What is the office address of Ritesh Parajuli, MD?

Is there any support for travel costs?